Wei Na Lu

20090004852, Jan 1, 2009

Dec 9, 2005

10/588833

Charles M. Lieber - Lexington MA, US
Yue Wu - Cambridge MA, US
Jie Xiang - Cambridge MA, US
Chen Yang - Somerville MA, US
Wei Lu - Ann Arbor MI, US

President and Fellows of Havard College - Cambridge MA

H01L 21/44

438664, 257E21199

A network element (), such as a Packet Data Serving Node, detects () a change in operational status of a mobile station during a communication session and, in response to detecting such a change, automatically increases () memory capacity as is available to support additional communication sessions while simultaneously persisting at least some session information for potential subsequent use during the communication session. For example, this response can occur upon detecting that a mobile station has changed from an active to a dormant status. Then, upon returning to an active status, the network element can use the persisted information to facilitate rapid reconstruction of infrastructure support for the mobile station's call participation.

20110001117, Jan 6, 2011

Jan 21, 2009

12/746791

Charles M. Lieber - Lexington MA, US
Yajie Dong - Cambridge MA, US
Wei Lu - Ann Arbor MI, US
Guihua Yu - Cambridge MA, US

President and Fellows of Harvard College - Cambridge MA

H01L 29/66
H01L 21/60

257 9, 438468, 977762, 257E29168, 257E21506

The present invention generally relates to nanotechnology and sub-microelectronic devices that can be used in circuitry, and, in particular, to nanoscale wires and other nanostructures able to encode data. One aspect of the present invention is directed to a device comprising an electrical crossbar array comprising at least two crossed wires at a cross point. In some cases, at least one of the crossed wires is a nanoscale wire, and in certain instances, at least one of the crossed wires is a nanoscale wire comprising a core and at least one shell surrounding the core. For instance, the core may comprise a crystal (e.g., crystalline silicon) and the shell may be at least partially amorphous (e.g., amorphous silicon). In certain embodiments, the cross point may exhibit intrinsic current rectification, or other electrical behaviors, and the cross point can be used as a memory device. For example, in one embodiment, the cross point may exhibit a first conductance at a positive voltage, and the cross point may exhibit a second conductance at a negative voltage. Accordingly, by applying suitable voltages to the cross point, data may be stored at the cross point. Other aspects of the present invention are directed to systems and methods for making or using such devices, kits involving such devices, or the like.

20230125739, Apr 27, 2023

Nov 9, 2022

17/984069

- Watertown MA, US
Anna Ericsson - Shrewsbury MA, US
Ann-Marie Campbell - Monroe CT, US
Gary Gustafson - Ridgefield CT, US
Zhongguo Wang - Lexington MA, US
R. Bruce Diebold - Waltham MA, US
Susan Ashwell - Carlisle MA, US
Justin Andrew Caravella - Cambridge MA, US
Wei Lu - Newton MA, US

FORMA Therapeutics, Inc. - Watertown MA

C07D 401/12
C07D 401/14
C07D 471/04
A61P 35/00

The invention relates to inhibitors of mutant isocitrate dehydrogenase (mt-IDH) proteins with neomorphic activity useful in the treatment of cell-proliferation disorders and cancers, having the Formula:where A, U, W, W, W, R-R, and Rare described herein.

20230101121, Mar 30, 2023

Nov 14, 2022

17/986414

- Watertown MA, US
Alan Collis - Lexington MA, US
Jeff Davis - Hingham MA, US
Duncan Walker - Boulder CO, US
Susan Ashwell - Carlisle MA, US
Blythe Thomson - Cincinnati OH, US
Wei Lu - Newton MA, US

FORMA Therapeutics, Inc. - Watertown MA

A61K 31/4709
A61P 35/02
C12Q 1/686
C12Q 1/6886

Methods of treating patients diagnosed with AML or MDS harboring mutant IDH-1 include detecting an IDH1 mutation and the therapeutic administration of an inhibitor of a mutant IDH-1 as a single agent, or in combination with azacitidine (AZA) or cytarabine.

20230066088, Mar 2, 2023

Mar 21, 2022

17/700027

- Watertown MA, US
Susan Ashwell - Carlisle MA, US
Blythe Thomson - Cincinnati OH, US
Alan Collis - Lexington MA, US
Jeff Davis - Hingham MA, US
Duncan Walker - Boulder CO, US
Wei Lu - Newton MA, US

A61K 31/4709
A61P 35/00

Patients diagnosed with a cancer harboring an IDH-1 mutation can be treated by the administration of a therapeutically effective amount of a pharmaceutical composition comprising Compound 1, a selective inhibitor of 2-HG production from mIDH-1 enzymes including the R132 mutations R132C, R132H, R132L, R132G, and R132S.

20210214323, Jul 15, 2021

Feb 26, 2021

17/187061

- Watertown MA, US
Hongbin LI - Watertown MA, US
James Loch - Watertown MA, US
Wei Lu - Newton MA, US
Matthew W. Martin - Arlington MA, US
David S. Millan - Watertown MA, US
Shawn E.R. Schiller - Watertown MA, US
Mark J. Tebbe - Arlington MA, US

C07D 295/192
A61K 45/06
C07D 215/14
C07D 231/56
C07D 405/12
C07D 413/12
C07D 417/12
C07D 471/04
C07D 257/04
C07D 487/04
C07D 263/57
C07D 491/048
C07D 271/12
C07D 495/04
C07D 209/18
C07D 277/62
C07D 277/66
C07D 513/04
C07D 213/56
C07D 305/08
A61K 31/4965
A61P 35/00
A61K 31/495
A61K 31/496
A61K 31/497
A61K 31/4985
A61K 31/5025
A61K 31/506
C07D 209/08
C07D 213/65
C07D 213/69
C07D 217/16
C07D 231/12
C07D 235/08
C07D 401/04
C07D 403/04
C07D 417/04

The present invention relates to compounds and composition for inhibition of FASN, their synthesis, applications, and antidotes. An illustrative compound of the invention is shown below:

20210085669, Mar 25, 2021

Dec 4, 2020

17/112269

- Watertown MA, US
Alan Collis - Lexington MA, US
Jeff Davis - Hingham MA, US
Duncan Walker - Boulder CO, US
Susan Ashwell - Carlisle MA, US
Blythe Thomson - Cincinnati OH, US
Wei Lu - Newton MA, US

A61K 31/4709
A61P 35/02
C12Q 1/686
C12Q 1/6886

Methods of treating patients diagnosed with AML or MDS harboring mutant IDH-1 include detecting an IDH1 mutation and the therapeutic administration of an inhibitor of a mutant IDH-1 as a single agent, or in combination with azacitidine (AZA) or cytarabine.

20210078973, Mar 18, 2021

Nov 23, 2020

17/101018

- Watertown MA, US
Anna Ericsson - Shrewsbury MA, US
Ann-Marie Campbell - Monroe CT, US
Gary Gustafson - Ridgefield CT, US
Zhongguo Wang - Lexington MA, US
R. Bruce Diebold - Waltham MA, US
Susan Ashwell - Carlisle MA, US
Justin Andrew Caravella - Cambridge MA, US
Wei Lu - Newton MA, US

C07D 401/12
C07D 401/14
C07D 471/04
A61P 35/00

The invention relates to inhibitors of mutant isocitrate dehydrogenase (mt-IDH) proteins with neomorphic activity useful in the treatment of cell-proliferation disorders and cancers, having the Formula:where A, U, W, W, W, R-R, and Rare described herein.